OncoMatch/Clinical Trials/NCT06356688
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Is NCT06356688 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Paclitaxel Polymeric Micelles for for locally advanced esophageal squamous cell carcinoma.
Treatment: Paclitaxel Polymeric Micelles for — The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (Cadonilimab) in combination with platinum-containing chemotherapy (Paclitaxel Polymeric Micelles for Injection combined with Cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of Cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with Cadonilimab combined with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT2-4AN+, CT3-4AN0, II, III, IVA (AJCC 8th edition cTNM)
Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable...clinical stage cT2-4aN+ or cT3-4aN0, M0, stage II, III, or IVA (AJCC 8th edition cTNM staging)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy
Cannot have received: radiotherapy
No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy
Cannot have received: immunotherapy
No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy
Cannot have received: surgery
Patients who have previously received anti-tumor therapy (including chemotherapy, radiotherapy, surgery or immunotherapy, etc.)
Lab requirements
Blood counts
WBC ≥3×10^9/L, ANC ≥1.5×10^9/L, PLT ≥100×10^9/L, Hb ≥9g/dL
Kidney function
cCr>40 ml/min, Cr≤1.5 ULN
Liver function
TBIL ≤2ULN, AST ≤2.5ULN, ALT ≤2.5ULN
Cardiac function
no cardiac disease or coronary artery disease, cardiac function grade 1-2
Adequate baseline organ function: (i) WBC ≥3×10^9/L, ANC ≥1.5×10^9/L, PLT ≥100×10^9/L, Hb ≥9g/dL; (ii) Liver function: TBIL ≤2ULN, AST ≤2.5ULN, ALT ≤2.5ULN; (iii) Renal function: cCr>40 ml/min, Cr≤1.5 ULN; (iv) Cardiac function: no cardiac disease or coronary artery disease. Cardiac function: no heart disease or coronary heart disease, patients with cardiac function grade 1-2;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06356688 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT2-4AN+ or CT3-4AN0 or II or III or IVA is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages